Yale’s rapid COVID-19 saliva test receives FDA emergency use authorization. 該校挺耶魯大學公共衛生學院(YSPH)公開聲明支持Dr. Harvey Risch的學術自由

以色列也有在等待官方批准的唾液檢測法。


A quick and affordable saliva COVID-19 test — developed by Yale scientists and used by the NBA — has received FDA emergency use authorization.
#covid19


NEWS.YALE.EDU
Yale’s rapid COVID-19 saliva test receives FDA emergency use authorization
The YSPH-developed test, called SalivaDirect, has been used as part of an NBA testing program and will now be available to more diagnostic laboratories.




****https://hcnew.blogspot.com/2020/07/hydroxychloroquine-lowers-covid-19.html
8月3日晚間，無意間在CNN的新聞報導，看到主持人電訊訪談力主"羥氯喹可降低COVID-19死亡率"的耶魯大學名教授Dr. Harvey Risch (他的論點/論文發表在American Journal of Epidemiology )。
如前述，"大部分專家"同意FDA的說法，可是耶魯大學公共衛生學院(YSPH)公開聲明支持Dr. Harvey Risch的學術自由，主張反對Dr. Harvey Risch者必須循學術正常管道提出說法和證據：

YSPH Statement Regarding Hydroxychloroquine < Yale ...publichealth.yale.edu › news-article5 日前 - Dr. Harvey Risch is a distinguished cancer epidemiologist who has opined on the topic of hydroxychloroquine (HCQ) and COVID-19 out-patient therapy. He has written a review article in the American Journal of Epidemiology ...

這是美國制度的可貴：請拿出證據說服我。雖然Dr. Harvey Risch等是非主流/官方說法(Dr. Harvey Risch說，說，FDA的實驗，從來非隨機化，此次它所實驗的病人，都是送入醫院的病重者(In-patient)，對於未送入醫院的症狀較輕者，羥氯喹可降低COVID-19死亡率)，還是尊重。